R&D
A global pioneer in the development of new drugs
Our Medicines
SK Biopharmaceuticals and its U.S. subsidiary SK Life Science independently developed XCOPRI® (cenobamate) from inception through to the FDA approval.
SK Biopharmaceuticals also discovered and licensed-out the FDA and EMA-approved treatment
SUNOSI® (solriamfetol)* after completing phase 1 clinical trials.
SUNOSI® (solriamfetol)* after completing phase 1 clinical trials.
* Axsome Therapeutics holds rights to develop and commercialize solriamfetol worldwide, excluding certain jurisdictions in Asia, while SK Biopharmaceuticals maintains rights for the 9 Asian markets.
You are about to leave this website. This link will take you to a site maintained by a third party. SK Biopharmaceuticals is not responsible for its contents.